Clinical trial
SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC
NCT05583409
Study timeline
Study start (estimated)2023-01-01Date precision: day
Registry last updated2022-10-17
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
Stage IV Non-small Cell Lung Cancerunresolved
Interventions
SBRT+OsimertinibRADIATION
Osimertinib 80 MGDRUG · verified · RxNorm: osimertinib 80 MG
Sponsors & collaborators
Li Zhanglead sponsor
Hubei Cancer Hospitalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT05583409 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.